Forest Buys Clinical Data And Extends Its Antidepressant Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The Lexapro maker will pay $1.2 billion upfront plus potential milestones to gain a recently approved antidepressant Viibryd.
You may also be interested in...
Blend Hopes To Improve Upon Performance Of Antibody-Drug Conjugates
While its most advanced program is a prodrug of cisplatin designed to enter tumors as they absorb albumin, Blend is particularly excited about Pentarins, its novel class of conjugated cancer therapeutics.
Brintellix Label Gives Lundbeck Ground For Tolerability Claims
Lundbeck/Takeda’s newly approved antidepressant Brintellix is poised to enter the crowded, genericized antidepressant market at the end of 2013. Potential advantages in labeling include flexible dosing, lack of weight gain and lower rates of sexual dysfunction compared to some other drugs.
Will Saunders Bring Transformation To Forest?
The specialty pharma long has been scrutinized for its decisions regarding the patent cliff and business development. Now, a new CEO will have the chance to keep the company on its current course or mirror the transformations he’s put in motion at other companies.